Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA090559, K08 CA255574)
U.S. Department of Health & Human Services | NIH | Center for Scientific Review (T32 GM132083)
Received: 24 September 2021
Accepted: 29 June 2022
First Online: 15 August 2022
: D.N.K. has been a consultant for Merck Sharp & Dohme with regard to intellectual property rights and for AbbVie and PsiOxus Therapeutics Ltd with regard to provision of services. E.P.P. has received support from Intuitive Surgical. Q.S. reports a consulting or advisory role with Yiviva, Boehringer Ingelheim Pharmaceuticals, Regeneron Pharmaceuticals, Hoosier Cancer Research Network (to self), an honorarium or speaker role with Chugai Pharmaceutical Co., stocks from Johnson & Johnson, Amgen and Merck & CO. (to self), and research funds from Celgene/BMS, Roche/Genentech, Janssen and Novartis (to institution). D.B.S. has consulted for and received honoraria from Pfizer, Lilly/Loxo Oncology, Vividion Therapeutics, Scorpion Therapeutics and BridgeBio. M.F.B. has consulted for Eli Lilly and PetDx, and has received research funding from Grail not related to the work presented. P.B.R. is an EMD Serono consultant and reports support for travel from Elekta and Philips healthcare and prior research funding from EMD Serono. R.Y. has been an advisor for Pfizer, Mirati Therapeutics and Natera, and has received research support from Pfizer, Boehringer Ingelheim and Forte Biosciences. J.J.S. has received travel support from Intuitive Surgical for fellow education and has served as a clinical advisor for Guardant Health. J.G.-A. has received an honorarium for being a consultant with Medtronics, Ethicon, Johnson & Johnson and Intuitive Surgical, and owns stock in Intuitive Surgical. All other authors have no competing interests.